Skip to main content
. 2017 Jun 16;6(9):e1339853. doi: 10.1080/2162402X.2017.1339853

Figure 2.

Figure 2.

NK cell degranulation correlates with elotuzumab concentration. A) Percentage CD56dim NK cells in PBMC from 3 healthy donors degranulating after 2 hours with various concentrations (0.001–100µg/ml) of Elo alone (left) or with MM.1R targets (right; PBMC to target cell ratio 1:1). B) Viability of CD56dim NK cells as the percentage of propidium iodide (PI)-negative CD56dim NK cells for each condition.